N. Wolmark

发表

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

J. Cuzick, J. Bergh, R. Peto, 2022, The Lancet. Oncology.

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial.

W. Symmans, H. Rugo, S. Loibl, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

R. Greil, E. Winer, H. Rugo, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The relationship of depth of penetration and tumor size to the number of positive nodes in dukes C colorectal cancer

B. Fisher, E. Fisher, H. Wieand, 1984, Cancer.

A randomized trial of five years of letrozole versus placebo after aromatase inhibitor-based therapy: NRG Oncology/NSABP B-42

S. Paik, C. Geyer, S. Swain, 2019 .

Geometric Resistance and Microvascular Network Architecture of Human Colorectal Carcinoma

R K Jain, T C Skalak, R. Jain, 1997, Microcirculation.

Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE

A. Schneeweiss, S. Loibl, M. Untch, 2019, General Session Abstracts.

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

T. Julian, C. Geyer, P. Ward, 2021, Breast Cancer Research and Treatment.

119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial

W. Symmans, M. Untch, J. Huober, 2021, Annals of Oncology.

Current Activities of the Coalition of Cancer Cooperative Groups

W. Curran, M. Bertagnolli, J. Dancey, 2019 .

Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.

E. Oki, F. Baehner, A. Venook, 2022, Journal of gastrointestinal oncology.

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

N. Loman, Jenny C. Chang, Chiun-Sheng Huang, 2022, npj Breast Cancer.

Observations following Corynebacterium parvum administration to patients with advanced malignancy. A phase I study

N. Wolmark, B. Fisher, H. Rubin, 1976, Cancer.

New concepts in the management of primary breast cancer

N. Wolmark, B. Fisher, N. Wolmark, 1975, Cancer.

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

C. Denkert, W. Symmans, H. Rugo, 2021, npj Breast Cancer.

Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B‐17: Five‐year observations concerning lobular carcinoma in situ

S. Paik, B. Fisher, E. Fisher, 1996, Cancer.

Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight‐year update of Protocol B‐17

J Costantino, S. Paik, B. Fisher, 1999, Cancer.

The Role of Tamoxifen in Breast Cancer Prevention

B. Dunn, N. Wolmark, 2001, Annals of the New York Academy of Sciences.

Findings from NSABP protocol no. b‐04: Comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial‐central breast cancers

C. Redmond, B. Fisher, E. Fisher, 1981, Cancer.

Fifteen‐year prognostic discriminants for invasive breast carcinoma

B Fisher, B. Fisher, E. Fisher, 2001, Cancer.

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer

E. Perez, C. Geyer, P. Ward, 2022, Breast Cancer Research and Treatment.

Disease‐free survival at intervals during and following completion of adjuvant chemotherapy: The NSABP experience from three breast cancer protocols

C. Redmond, N. Wolmark, B. Fisher, 1981, Cancer.

Preliminary observations on the use of corynebacterium parvum in patients with primary intracranial tumors: Effect on intracranial pressure

R. Selker, N. Wolmark, P. Moore, 1978, Journal of surgical oncology.

Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma

Adrian V. Lee, Yusi Fang, S. Oesterreich, 2023, British Journal of Cancer.

The triple-stapled colonic anastomosis

T. Julian, R. Kolachalam, N. Wolmark, 1989, Diseases of the colon and rectum.

Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC).

G. Yothers, T. George, L. Kachnic, 2023, Journal of Clinical Oncology.

Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41

S. Paik, G. Tang, C. Geyer, 2023, Breast Cancer Research and Treatment.

National Surgical Adjuvant Breast and Bowel Project

N. Wolmark, Lori Garvey, 2020, Definitions.

Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)

C. Geyer, S. Loibl, M. Untch, 2019, Annals of Oncology.

96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE

N. Loman, Jenny C. Chang, C. Geyer, 2020 .

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, hormone receptor+, HER2-, RS ≤18 breast cancer.

R. Jagsi, T. Julian, R. Zellars, 2022, Journal of Clinical Oncology.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy

A. Schneeweiss, R. Gelber, M. Buyse, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

P. Philip, S. Kopetz, G. Yothers, 2023, Journal of Clinical Oncology.

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

C. Denkert, W. Symmans, H. Rugo, 2021, npj Breast Cancer.

NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).

P. Philip, S. Kopetz, G. Yothers, 2022, Journal of Clinical Oncology.

Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

H. Rockette, N. Wolmark, H. Bear, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer.

B Fisher, J Costantino, C. Redmond, 1993, The New England journal of medicine.

Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience.

N. Wolmark, E. Mamounas, B. Fisher, 2001, Seminars in oncology.

Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer.

B Fisher, C. Redmond, N. Wolmark, 1985, The New England journal of medicine.

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.

J. Bryant, N. Wolmark, E. Mamounas, 2001, Journal of the National Cancer Institute. Monographs.

Interstitial hypertension in human breast and colorectal tumors.

R K Jain, R. Jain, Y. Boucher, 1992, Cancer research.

Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial

E. Perez, S. Paik, C. Geyer, 2023, Frontiers in Oncology.

Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.

J F Silverman, T. Julian, N. Wolmark, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

Anna L. Brown, J. Bryant, D. Wickerham, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01.

H. Rockette, C. Redmond, D. Wickerham, 1988, Journal of the National Cancer Institute.

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

C K Redmond, B Fisher, C. Redmond, 1999, Journal of the National Cancer Institute.

The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.

H. Rockette, C. Redmond, N. Petrelli, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

T. Walsh, M. King, L. Ford, 2001, JAMA.

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.

S. Paik, J. Bryant, D. Wickerham, 2000, Journal of the National Cancer Institute.

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

B Fisher, S. Paik, J. Bryant, 1998, Journal of the National Cancer Institute.

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

D. Wickerham, N. Wolmark, E. Mamounas, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.

H. Rockette, N. Petrelli, D. Wickerham, 2000, Journal of the National Cancer Institute.

Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.

H. Rockette, D. Wickerham, N. Wolmark, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01.

H. Rockette, C. Redmond, D. Wickerham, 1988, Journal of the National Cancer Institute.

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

A. Schneeweiss, R. Gelber, M. Buyse, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

J. Bryant, D. Wickerham, H. Bear, 2023, Journal of Clinical Oncology.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

L. Ford, J. Costantino, D. Wickerham, 2005, Journal of the National Cancer Institute.

The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04.

N. Petrelli, R. Beart, N. Wolmark, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Prognostic Significance of Preoperative Carcinoembryonic Antigen Levels in Colorectal Cancer: Results from NSABP Clinical Trials

N. Wolmark, B. Fisher, N. Dimitrov, 1984 .

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

C. Redmond, J. Costantino, D. Wickerham, 1989, The New England journal of medicine.

Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project.

D. Wickerham, N. Wolmark, Roy E. Smith, 1999, Journal of the National Cancer Institute.

Significance of ipsilateral breast tumour recurrence after lumpectomy

C. Redmond, D. Wickerham, N. Wolmark, 1991, The Lancet.

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.

J. Bryant, N. Wolmark, B. Fisher, 2001, Journal of the National Cancer Institute.

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

B Fisher, J Costantino, C. Redmond, 1996, Journal of the National Cancer Institute.

GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

C. Denkert, S. Loibl, V. Nekljudova, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.

C. Redmond, D. Wickerham, N. Wolmark, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials.

H. Rockette, H. Wieand, N. Wolmark, 1983, Annals of surgery.

The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer.

H E Rockette, H. Rockette, P. Johnston, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.

C. Redmond, R. Foster, D. Wickerham, 1989, The New England journal of medicine.

Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer.

B Fisher, C. Redmond, N. Wolmark, 1989, The New England journal of medicine.

Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

J. Costantino, D. Wickerham, N. Wolmark, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.

B Fisher, J. Bryant, D. Wickerham, 1997, Journal of the National Cancer Institute.

Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.

N. Wolmark, B. Fisher, E. Fisher, 2001, Journal of the National Cancer Institute.

Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02.

H. Rockette, C. Redmond, D. Wickerham, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe

Anna L. Brown, C. Redmond, D. Wickerham, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

D. Wickerham, N. Wolmark, S. Anderson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.

N. Wolmark, S. Wieand, L. Colangelo, 2001, Seminars in oncology.

Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.

C. Redmond, D. Wickerham, N. Wolmark, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term tamoxifen citrate use and potential ocular toxicity.

C. Redmond, J. Costantino, N. Wolmark, 1998, American journal of ophthalmology.

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.

J. Bryant, B. Fisher, Jiping Wang, 2001, Journal of the National Cancer Institute. Monographs.

Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.

J. Bryant, N. Wolmark, J. Grem, 1998, Journal of the National Cancer Institute.

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.

B Fisher, C. Redmond, D. Wickerham, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

National Surgical Adjuvant Breast and Bowel Project

B. Fisher, Bernard Fisher, N. Wolmark, 2020, Definitions.

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/ NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer

S. Paik, J. Costantino, C. Geyer, 2019 .

Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.

D. Wickerham, N. Wolmark, S. Anderson, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.

M Buyse, D. Sargent, M. Buyse, 2011, European journal of cancer.

Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials

R. Gelber, A. Tutt, M. Piccart, 2023, The Lancet.

Studies concerning the regional lymph node in cancer VIII. Effect of two asynchronous tumor foci on lymph node cell cytotoxicity

N. Wolmark, B. Fisher, E. Fisher, 1975, Cancer.

Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project.

B Fisher, J. Bryant, N. Wolmark, 1998, Controlled clinical trials.

Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.

N. Wolmark, R. Goldberg, J. Marshall, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.

D. Wickerham, N. Wolmark, E. Mamounas, 2001, Journal of the National Cancer Institute. Monographs.

Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.

J. Krauss, C. Allegra, G. Yothers, 2022, Journal of Clinical Oncology.